Patents Assigned to Dynamis Therapeutics, Inc.
  • Patent number: 9555012
    Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: January 31, 2017
    Assignee: Dynamis Therapeutics, Inc.
    Inventor: Annette Tobia
  • Patent number: 9446007
    Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: September 20, 2016
    Assignees: Dynamis Therapeutics, Inc., Lankenau Institute for Medical Research
    Inventors: Annette Tobia, Arturo Bravo Nuevo, Lisa Laury-Kleintop
  • Publication number: 20140045947
    Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicant: Dynamis Therapeutics, Inc.
    Inventor: Annette Tobia
  • Publication number: 20100310482
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Application
    Filed: June 3, 2010
    Publication date: December 9, 2010
    Applicant: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20100297046
    Abstract: The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 25, 2010
    Applicant: DYNAMIS THERAPEUTICS, INC.
    Inventors: Michael Schwartz, Francis Kappler, Bangying Su
  • Patent number: 7749503
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: July 6, 2010
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Patent number: 7671019
    Abstract: The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG synthesis, is also present in the skin. Thus, the invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: March 2, 2010
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Patent number: 7622117
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: November 24, 2009
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20080292568
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Application
    Filed: June 15, 2007
    Publication date: November 27, 2008
    Applicant: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler